GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » EV-to-FCF

NervGen Pharma (TSXV:NGEN) EV-to-FCF : -10.52 (As of Dec. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NervGen Pharma's Enterprise Value is C$171.06 Mil. NervGen Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-16.27 Mil. Therefore, NervGen Pharma's EV-to-FCF for today is -10.52.

The historical rank and industry rank for NervGen Pharma's EV-to-FCF or its related term are showing as below:

TSXV:NGEN' s EV-to-FCF Range Over the Past 10 Years
Min: -20.27   Med: 0   Max: 0
Current: -10.04

TSXV:NGEN's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs TSXV:NGEN: -10.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), NervGen Pharma's stock price is C$2.73. NervGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.370. Therefore, NervGen Pharma's PE Ratio (TTM) for today is At Loss.


NervGen Pharma EV-to-FCF Historical Data

The historical data trend for NervGen Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma EV-to-FCF Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -6.60 -11.56 -13.13 -4.04 -13.07

NervGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.52 -13.07 -12.67 -13.56 -9.80

Competitive Comparison of NervGen Pharma's EV-to-FCF

For the Biotechnology subindustry, NervGen Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's EV-to-FCF falls into.



NervGen Pharma EV-to-FCF Calculation

NervGen Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=171.062/-16.267
=-10.52

NervGen Pharma's current Enterprise Value is C$171.06 Mil.
NervGen Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-16.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (TSXV:NGEN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

NervGen Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.73/-0.370
=At Loss

NervGen Pharma's share price for today is C$2.73.
NervGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.370.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


NervGen Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Executives
John Ruffolo Director
Krista Mckerracher Director
William Joseph Radvak Director
Harold Punnett 10% Security Holder, Director
Robert Pilz Senior Officer

NervGen Pharma Headlines

No Headlines